arrow_back Civic Audit
Share share

Lower Costs for Inhalers and Nebulizers for Patients

This act aims to reduce the cost of prescription inhaler products and related equipment for breathing disorders like asthma and COPD. It caps patient cost-sharing at $15 per 30-day supply and eliminates deductibles, making essential treatments more accessible.
Key points
Patient cost-sharing for a 30-day supply of specified inhaler products will not exceed $15.
Health plans cannot apply deductibles to specified inhaler products.
These changes will apply to private insurance, Medicare (Parts B and D), and programs for uninsured individuals, effective January 1, 2026.
Cost-sharing amounts will count towards out-of-pocket maximums.
article Official text account_balance Process page notifications_active Track this Bill
Status: Introduced
Civic Will
Checking votes...
I support
I oppose
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_HR_5278
Sponsor: Rep. Mfume, Kweisi [D-MD-7]
Process start date: 2025-09-10
System Note: Lustra is free, publicly auditable civic infrastructure — full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source—always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Affordable Inhalers and Nebulizers Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_5278.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2025-09-10.

What are the main provisions?

Key points include:

  • Patient cost-sharing for a 30-day supply of specified inhaler products will not exceed $15.
  • Health plans cannot apply deductibles to specified inhaler products.
  • These changes will apply to private insurance, Medicare (Parts B and D), and programs for uninsured individuals, effective January 1, 2026.
  • Cost-sharing amounts will count towards out-of-pocket maximums.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Mfume, Kweisi [D-MD-7].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

What is the impact of this bill?

We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health